QHP Capital, L.P. (“QHP”), an investor in technology and services companies in the life sciences and healthcare sectors, announced its sale of Pro-ficiency, LLC (“Pro-ficiency” or the “Company”), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy.
Michael Raymer, Chief Executive Officer of Pro-ficiency, said, “We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations within the pharmaceutical and biotech community. Both teams approached this transaction with a growth mentality. We look forward to leveraging Simulations Plus’ specialized offerings and business development infrastructure to expand our combined market reach. Finally, our operations are complementary, our cultures are aligned, and together we believe we can elevate the performance of our mutual clients as well as attract new ones with our end-to-end solutions.”
QHP Capital made its original investment in Pro-ficiency in 2021. The Company then completed several additional acquisitions in the investment period with Fugitive Labs, LLC in 2022 and Compass Group Partners in 2023.
“We are very pleased with the growth and innovation we have seen these past few years at Pro-ficiency. We are excited to see them continue to improve clinical development as part of the SLP offering," said Michael Sorensen, Partner at QHP Capital.
To view the original press release, please click here.
